John Francis Lyons
14Patents
6h-index
35Co-inventors
66Inventor score
Filing activity: May 22, 1998 → Mar 28, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6998391B2 | Method for treating diseases associated with abnormal kinase activity | Human Necessities | 80 | Expired |
| US6187799A | Inhibition of raf kinase activity using aryl ureas | Chemistry; Metallurgy | 53 | Expired |
| US8399442B2 | Pharmaceutical compounds | Chemistry; Metallurgy | 41 | Active |
| US8277807B2 | Pharmaceutical combinations | Human Necessities | 31 | Active |
| US7307071B2 | RAF-MEK-ERK pathway inhibitors to treat cancer | Human Necessities | 22 | Expired |
| US8435970B2 | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea | Human Necessities | 8 | Active |
| US8404718B2 | Combinations of pyrazole kinase inhibitors | Human Necessities | 5 | Active |
| US11236047B2 | Combination of isoindolinone derivatives with SGI-110 | Human Necessities | 2 | Active |
| US8916552B2 | Pharmaceutical combinations | Human Necessities | 2 | Active |
| US8779132B2 | Pharmaceutical compounds | Chemistry; Metallurgy | 2 | Active |
| US8883790B2 | Pharmaceutical combinations | Human Necessities | 2 | Active |
| US9428439B2 | Hydrobenzamide derivatives as inhibitors of Hsp90 | Chemistry; Metallurgy | 2 | Active |
| US8541461B2 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | Human Necessities | 1 | Active |
| US6977247B2 | Sequential therapy comprising a 20(S)-camptothecin and a pyrimidine base analog | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.